KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.

Kelong Han, Parul Patel, Scott McCallister, Alex R Rinehart, Yash Gandhi, William Spreen, Raphael J Landovitz, Sinead Delany-Moretlwe, Mark A Marzinke, Todd McKeon, Piotr Budnik, Jean van Wyk, Susan L Ford

Antimicrob Agents Chemother 68(6) e0147523

PMID38709006
PMCIDPMC11620484
DOI10.1128/aac.01475-23
发表日期2024-05-06
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

UNLABELLED: Long-acting cabotegravir is approved for pre-exposure prophylaxis and combination HIV treatment, both initiated with optional short-term oral lead-in (OLI). We evaluated the impact of OLI on long-acting cabotegravir pharmacokinetics. Cabotegravir plasma concentrations were compared between HIV-positive participants initiating injections with (n = 278) or without (n = 110) OLI in phase III treatment study FLAIR and in HIV-negative participants using OLI (n = 263) in pivotal pre-exposure prophylaxis studies HPTN 083 and HPTN 084. Cabotegravir pharmacokinetic profiles were simulated in three populations (assigned-male-at-birth, 50%-assigned-female-at-birth, and assigned-female-at-birth) under three scenarios: first injection given (A) 1 or (B) 3 days after final OLI dose (OLI-injection gap) or (C) without OLI. The PK objective was 80% of participants achieving 4× in vitro protein-adjusted 90% maximal inhibitory concentration (PA-IC90) and 50% achieving 8× PA-IC90. Observed trough concentrations (Cτ) were similar with and without OLI (P > 0.3). With a 3-day OLI-injection gap, simulated pre-injection Cτ remained above PK objective. Approximately 1-2 weeks after the first injection, simulated PK profiles became nearly identical among all scenarios. Without OLI, it was predicted that 80% of participants achieve 4× PA-IC90 in 1.2, 1.8, and 2.8 days after the first injection in each population, respectively, and 50% achieve 8× PA-IC90 in 1.4, 2.1, and 3.8 days, respectively. Observed long-acting cabotegravir exposure was similar with or without OLI, supporting optional OLI use. Cabotegravir exposure was predicted to remain above PK objective for OLI-injection gaps of ≤3 days and rapidly achieve PK objective after first injection without OLI. Findings are consistent between assigned-male-at-birth and assigned-female-at-birth populations. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT02720094.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。